INTRODUCTION {#s1}
============

Medullary breast carcinoma (MBC) accounts for less than 5% of all invasive breast cancers. The clinicopathological characteristics and outcomes in MBC make it unique from infiltrating ductal carcinoma-not otherwise specified (IDC-NOS) \[[@R1]\].

MBC is characterized by a young age, a large tumor size, a high nuclear grade \[[@R2]--[@R4]\]. And some studies found that the MBCs seemed to exhibit a significantly higher proportion of triple-negative phenotype (absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2)) based on a gene expression analysis or immunohistochemical staining \[[@R5], [@R6]\]. As is known to all, triple-negative breast cancer (TNBC) usually is relevant to a worse prognosis. However, though patients with MBC show aggressive histological features, there is no consensus regarding difference of clinicopathological characteristics and outcomes between MBC and IDC. Some studies have revealed that MBC histology is associated with a favorable prognosis \[[@R2], [@R5], [@R7]--[@R9]\]. Other studies did not confirm this conclusion and even some indicated the prognosis of MBC did not differ from IDC \[[@R10]--[@R12]\].

Identification of prognostic factors is important for MBC patients so as to not only dictate diagnosis but also provide more appropriate treatment. Martinez et al. reported that in multivariate analysis, advanced age, black race, regional metastases, distant metastases, increased tumor size, ER positivity and increased lymph node metastasis (LNM) were associated with decreased overall survival in a cohort of MBC patients \[[@R13]\]. Park et al. identified there was no difference in disease-free survival (DFS) or overall survival (OS) among MBC patients according to tumor size, hormone receptor status, HER2 status, or adjuvant treatment but patients with lymph nodes metastasis presented a worse DFS and OS \[[@R12]\]. Based on small numbers of patients, different populations of studies and lacked adjustment of confounds, these prognostic factors specific to MBC are relatively unclear.

Given the controversial data on the prognosis of MBC, this study was designed to identify difference in characteristics and outcomes between MBC and IDC, and further confirm the factors related to prognosis of MBC by utilizing Surveillance, Epidemiology, and End Results (SEER), a large population-based database.

RESULTS {#s2}
=======

Demographics and clinical characteristics of study population {#s2_1}
-------------------------------------------------------------

A total of 84,764 patients met the eligibility criteria for our study, including 309 (0.36%) MBC patients and 84,455 (99.64%) IDC patients. Table [1](#T1){ref-type="table"} summarizes all of the demographic and clinical characteristics by histological subtype. There were significant differences in the characteristics including age of diagnosis, race, grade, American Joint Committee on Cancer (AJCC) stage, tumor size and breast subtype. MBC patients showed a younger age at diagnosis (42.1% vs. 24.0%, *P* \< 0.001) and a poorer grade (grade III and IV, 93.5% vs. 36.2%, *P* \< 0.001) than IDC patients. In addition, MBCs were much more likely to have a significantly higher proportion of black race (23.3% vs. 10.4%, *P* \< 0.001) and the AJCC stage of II (52.8% vs. 33.8%, *P* \< 0.001) than IDCs. Compared with IDC patients, MBC patients had larger tumor size (more tumors \> 2 cm and ≤ 5 cm in size, 50.2% vs. 29.2%, *P* \< 0.001). With regard to breast subtype, the MBC patients seemed more inclined to present TNBC compared with the IDC patients (56.0% vs. 13.1%, *P* \< 0.001). The other tumor characteristics, including married status, laterality, lymph node (LN) status, types of surgery and radiation therapy were similarly distributed between the two histological types.

###### Characteristics of patients with medullary breast carcinoma and invasive ductal carcinoma

  Characteristics                       MBC (*n* = 309)                                       IDC (*n* = 84455)   Total (*n* = 84764)   *P*[^c^](#tfn_003){ref-type="table-fn"}                         
  ------------------------------------- ----------------------------------------------------- ------------------- --------------------- ----------------------------------------- ------ ------- ------ --------------
  **Median follow-up (months) (IQ**R)   17 (9--27)                                            16 (8--25)          16 (8--25)                                                                            
  **Age (years)**                       **18--49**                                            130                 42.1                  20297                                     24.0   20427   24.1   \< 0.001
                                        **50--79**                                            179                 57.9                  64158                                     76.0   64337   75.9   
  Race                                  **White**                                             213                 68.9                  67456                                     79.9   67668   79.8   **\< 0.001**
                                        **Black**                                             72                  23.3                  8800                                      10.4   8872    10.5   
                                        **Other**[^a^](#tfn_001){ref-type="table-fn"}         24                  7.8                   8199                                      9.7    8223    9.7    
  **Marital statu**s                    **Married**                                           185                 59.9                  52200                                     61.8   52385   61.8   0.484
                                        **Not married**[^b^](#tfn_002){ref-type="table-fn"}   124                 40.1                  32255                                     38.2   32379   38.2   
  **Laterali**ty                        **Left**                                              150                 48.5                  42741                                     50.6   42891   50.6   0.469
                                        **Right**                                             159                 51.5                  41714                                     49.4   41873   49.4   
  Grade                                 **I**                                                 2                   0.6                   18452                                     21.8   18454   21.8   **\< 0.001**
                                        **II**                                                18                  5.8                   35405                                     41.9   35423   41.8   
                                        **III and IV**                                        289                 93.5                  30598                                     36.2   30887   36.4   
  AJCC stage                            **I**                                                 126                 40.8                  48567                                     57.5   48693   57.4   **\< 0.001**
                                        **II**                                                163                 52.8                  28542                                     33.8   28705   33.9   
                                        **III**                                               20                  6.5                   7346                                      8.7    7366    8.7    
  Tumor size (cm)                       **≤ 2**                                               141                 45.6                  56254                                     66.6   56395   66.5   **\< 0.001**
                                        **\> 2 and ≤ 5**                                      155                 50.2                  24645                                     29.2   24800   29.3   
                                        **\> 5**                                              13                  4.2                   3556                                      4.2    3569    4.2    
  Nodal status                          **0**                                                 240                 77.7                  60090                                     71.2   60330   71.2   0.087
                                        **1 to 3**                                            54                  17.5                  18459                                     21.9   18513   21.3   
                                        **4 to 10**                                           10                  3.2                   3998                                      4.7    4008    4.7    
                                        **\> 10**                                             5                   1.6                   1908                                      2.3    1913    2.3    
  **Breast subtype**                    **HR+/Her2−**                                         99                  32.0                  60267                                     71.4   60366   71.2   **\< 0.001**
                                        **HR+/Her2+**                                         10                  3.2                   9104                                      10.8   9114    10.8   
                                        **HR−/Her2+**                                         27                  8.7                   4028                                      4.8    4055    4.8    
                                        **Triple negative**                                   173                 56.0                  11056                                     13.1   11229   13.2   
  **Type of surgery**                   **BCS**                                               174                 56.3                  48311                                     57.2   48485   57.2   0.752
                                        **Mastectomy**                                        135                 43.7                  36144                                     42.8   36279   42.8   
  Radiation                             **No**                                                153                 49.5                  38055                                     45.1   38208   45.1   0.116
                                        **Yes**                                               156                 50.5                  46400                                     54.9   46556   54.9   

Abbreviation: MBC, medullary breast carcinoma; IDC, invasive ductal carcinoma; AJCC, American Joint Committee on Cancer; Her2, human epidermal growth factor receptor 2; HR, hormone receptor; BCS, breast conserving surgery; IQR, interquartile range.

Other includes American Indian/Alaskan native, and Asian/Pacific Islander.

Not married includes divorced, separated, single (never married), unmarried or domestic partner and widowed.

*P* value was calculated among all groups by the Chi-square test, and a bold type indicates significance.

Comparison of survival between MBCs and IDCs {#s2_2}
--------------------------------------------

Kaplan-Meier analysis was used to evaluate breast cancer-specific survival (BCSS) and overall survival (OS) in these two histological types (Figure [1](#F1){ref-type="fig"}). As it illustrated, patients with IDC had better survival than MBC patients in BCSS (*P* = 0.013), but they had similar OS (*P* = 0.184). In order to further investigate the prognostic factors, the results of the BCSS and OS analyses via univariate and multivariate Cox proportional hazard regression models were demonstrated in [Supplementary Table S1](#SD1){ref-type="supplementary-material"} and Table [2](#T2){ref-type="table"}, respectively. According to univariate analysis, not married status, grade III and IV, a tumor size of \> 5 cm, the increased number of lymph nodes, the subtype of TNBC and no receipt of radiation therapy were significantly associated with poor BCSS and OS, which were validated in the following multivariate analysis. However, after adjusting other prognostic factors, AJCC stage was no longer an independent prognostic factor in multivariate analysis. In the meantime, MBC patients showed significantly worse BCSS than IDC patients (univariate: hazard ratios, HRs = 2.483, 95% confidence interval, CI: 1.180--5.228, *P* = 0.017) and this result was no longer visible for OS.

![Kaplan-Meier plot and log-rank test compared breast cancer-specific survival (BCSS, A) and overall survival (OS, B) by histology for all patients, medullary breast carcinoma (MBC) vs. invasive ductal carcinoma (IDC)](oncotarget-07-22665-g001){#F1}

###### Multivariate Cox proportional hazard model of breast cancer-specific survival (BCSS) and overall survival (OS)

  Variables             BCSS                                                  OS                                                           
  --------------------- ----------------------------------------------------- ---------------------- -------------- ---------------------- --------------
  **Age (years)**       **18--49**                                            0.825 (0.701--0.971)   **0.020**      0.545 (0.480--0.618)   **\< 0.001**
                        **50--79**                                            Reference                             Reference              
  **Race**              **White**                                             Reference                             Reference              
                        **Black**                                             1.144 (0.946--1.383)   0.165          1.078 (0.944--1.232)   0.267
                        **Other**[^a^](#tfn_004){ref-type="table-fn"}         0.610 (0.442--0.842)   **0.003**      0.668 (0.544--0.819)   **\< 0.001**
  **Marital status**    **Married**                                           Reference                             Reference              
                        **Not married[^b^](#tfn_005){ref-type="table-fn"}**   1.290 (1.111--1.497)   **0.001**      1.562 (1.417--1.722)   **\< 0.001**
  **Grade**             **I**                                                 0.518 (0.329--0.816)   **0.005**      0.986 (0.834--1.166)   0.872
                        **II**                                                Reference                             Reference              
                        **III and IV**                                        2.719 (1.779--2.670)   **\< 0.001**   1.360 (1.941--2.403)   **\< 0.001**
  **Histology type**    **MBC**                                               1.304 (0.490--2.183)   0.931          1.518 (1.206--1.533)   0.188
                        **IDC**                                               Reference                             Reference              
  **AJCC stage**        **I**                                                 Reference                             Reference              
                        **II**                                                1.385 (0.976--1.965)   0.068          0.909 (0.730--1.131)   0.390
                        **III**                                               1.530 (0.890--2.630)   0.124          0.923 (0.618--1.377)   0.694
  **Tumor size (cm)**   **≤ 2**                                               Reference                             Reference              
                        **\> 2 and ≤ 5**                                      1.917 (1.458--2.520)   **\< 0.001**   1.776 (1.469--2.147)   **\< 0.001**
                        **\> 5**                                              4.006 (2.862--5.607)   **\< 0.001**   3.307 (2.580--4.239)   **\< 0.001**
  **Nodal status**      **0**                                                 Reference                             Reference              
                        **1 to 3**                                            1.860 (1.499--2.308)   **\< 0.001**   1.453 (1.260--1.676)   **\< 0.001**
                        **4 to 10**                                           3.011 (1.939--4.674)   **\< 0.001**   2.405 (1.693--3.415)   **\< 0.001**
                        **\> 10**                                             5.248 (3.440--8.005)   **\< 0.001**   3.673 (2.607--5.175)   **\< 0.001**
  **Breast subtype**    **HR+/Her2−**                                         Reference                             Reference              
                        **HR+/Her2+**                                         0.582 (0.422--0.802)   **0.001**      0.827 (0.690--0.991)   **0.039**
                        **HR−/Her2+**                                         1.449 (1.098--1.913)   **0.009**      1.247 (1.020--1.526)   **0.032**
                        **Triple negative**                                   3.044 (2.553--3.628)   **\< 0.001**   2.324 (2.055--2.628)   **\< 0.001**
  **Type of surgery**   **BCS**                                               Reference                             Reference              
                        **Mastectomy**                                        1.037 (0.875--1.229)   0.672          0.589 (0.769--0.959)   **0.007**
  **Radiation**         **No**                                                1.796 (1.533--2.105)   **\< 0.001**   2.396 (2.147--2.675)   **\< 0.001**
                        **Yes**                                               Reference                             Reference              

Abbreviation: AJCC, American Joint Committee on Cancer; MBC, medullary breast carcinoma; IDC, invasive ductal carcinoma; Her2, human epidermal growth factor receptor 2; HR, hormone receptor; BCS, breast conserving surgery; HRs, hazard ratios; CI, confidence interval; BCSS, breast cancer-specific survival; OS, overall survival.

Other includes American Indian/Alaskan native, and Asian/Pacific Islander.

Not married includes divorced, separated, single (never married), unmarried or domestic partner and widowed.

*P* value was adjusted by multivariate Cox proportional hazard regression model including all factors, as categorized in Table [2](#T2){ref-type="table"}, and a bold type indicates significance.

Survival estimates in matched group {#s2_3}
-----------------------------------

Considering the above confounding factors affecting breast cancer outcomes between MBC and IDC patients, we conducted a 1:1 (MBC/IDC) matched case--control analysis utilizing the propensity score matching method (Table [3](#T3){ref-type="table"}). We obtained a group of 618 patients, including 309 patients for each histology type. For matched groups, no significant difference in characteristics was observed between MBC and IDC. Furthermore, we found that IDC histology no longer presented better prognosis for either BCSS or OS (Figure [2](#F2){ref-type="fig"}, *P* = 0.840 and *P* = 0.513 for BCSS and OS, respectively).

###### Characteristics of patients with medullary breast carcinoma and invasive ductal carcinoma in 1:1 matched group

  Characteristics                       MBC (*n* = 309)                                       IDC (*n* = 309)   Total (*n* = 618)   *P*[^c^](#tfn_009){ref-type="table-fn"}                       
  ------------------------------------- ----------------------------------------------------- ----------------- ------------------- ----------------------------------------- ------ ----- ------ -----------
  **Median follow-up (months) (IQR)**   17 (9--27)                                            16 (8--25)        17 (8--26)                                                                        
  **Age (years)**                       **18--49**                                            130               42.1                106                                       34.3   236   38.2   **0.047**
                                        **50--79**                                            179               57.9                203                                       65.7   382   61.8   
  **Race**                              **White**                                             213               68.9                223                                       72.2   436   70.6   0.654
                                        **Black**                                             72                23.3                63                                        20.4   135   21.8   
                                        **Other**[^a^](#tfn_007){ref-type="table-fn"}         24                7.8                 23                                        7.4    47    7.6    
  **Marital status**                    **Married**                                           185               59.9                194                                       62.8   379   61.3   0.457
                                        **Not married**[^b^](#tfn_008){ref-type="table-fn"}   124               40.1                115                                       37.2   239   38.2   
  **Laterality**                        **Left**                                              150               48.5                157                                       50.8   307   49.7   0.573
                                        **Right**                                             159               51.5                152                                       49.2   311   50.3   
  **Grade**                             **I**                                                 2                 0.6                 2                                         0.6    4     0.6    1.000
                                        **II**                                                18                5.8                 18                                        5.8    36    5.8    
                                        **III and IV**                                        289               93.5                289                                       93.5   578   93.5   
  **AJCC stage**                        **I**                                                 126               40.8                126                                       40.8   252   40.8   1.000
                                        **II**                                                163               52.8                163                                       52.8   362   52.8   
                                        **III**                                               20                6.5                 20                                        6.5    40    6.5    
  **Tumor size (cm)**                   **≤ 2**                                               141               45.6                148                                       47.9   289   46.8   0.666
                                        \> **2 and ≤ 5**                                      155               50.2                145                                       46.9   300   48.5   
                                        **\> 5**                                              13                4.2                 16                                        5.2    29    4.7    
  **Nodal status**                      **0**                                                 240               77.7                222                                       71.8   462   74.8   0.216
                                        **1 to 3**                                            54                17.5                75                                        24.3   129   20.9   
                                        **4 to 10**                                           10                3.2                 8                                         2.6    18    2.9    
                                        **\> 10**                                             5                 1.6                 4                                         1.3    9     1.5    
  **Breast subtype**                    **HR+/Her2−**                                         99                32.0                99                                        32.0   198   32.0   1.000
                                        **HR+/Her2+**                                         10                3.2                 10                                        3.2    20    3.2    
                                        **HR−/Her2+**                                         27                8.7                 27                                        8.7    54    8.7    
                                        **Triple negative**                                   173               56.0                173                                       56.0   346   56.0   
  **Type of surgery**                   **BCS**                                               174               56.3                158                                       51.1   332   53.7   0.197
                                        **Mastectomy**                                        135               43.7                151                                       48.9   286   46.3   
  **Radiation**                         **No**                                                153               49.5                165                                       53.4   318   51.5   0.334
                                        **Yes**                                               156               50.5                144                                       46.6   300   48.5   

Abbreviation: MBC, medullary breast carcinoma; IDC, invasive ductal carcinoma; AJCC, American Joint Committee on Cancer; Her2, human epidermal growth factor receptor 2; HR, hormone receptor; BCS, breast conserving surgery; IQR, interquartile range.

Other includes American Indian/Alaskan native, and Asian/Pacific Islander.

Not married includes divorced, separated, single (never married), unmarried or domestic partner and widowed.

*P* value was calculated among all groups by the Chi-square test after matching on age, grade, AJCC stage, breast subtype, and a bold type indicates significance.

![Kaplan-Meier plot and log-rank test compared breast cancer-specific survival (BCSS, C) and overall survival (OS, D) by histology for 1:1 matched group, medullary breast carcinoma (MBC) vs. invasive ductal carcinoma (IDC)](oncotarget-07-22665-g002){#F2}

Baseline characteristics and survival outcomes in triple-negative subgroup {#s2_4}
--------------------------------------------------------------------------

MBC patients predominantly had TNBC according to molecular subtype (*P* \< 0.001). Therefore, we analyzed characteristics and survival outcomes of the patients limited to TNBC subgroup, which contained 173 MBC patients and 11,056 IDC patients ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). And we came to some results in accordance with the entire population. For example, compared to TNBC-IDC patients, TNBC-MBC patients had younger age at diagnosis, larger proportion of black race and higher grade. Discriminately, nodal status and type of surgery become the significantly independent prognosis factors. However, AJCC stage and tumor size were no longer statistically different. In addition, the comparison of BCSS and OS by Kaplan-Meier curves presented similar survival for TNBC-MBC patients and TNBC-IDC patients (Figure [3](#F3){ref-type="fig"}, *P* = 0.504 and *P* = 0.298 for BCSS and OS, respectively). Furthermore, we matched 173 TNBC-MBC patients to 173 TNBC-IDC patients adjusted by age, AJCC stage and grade, utilizing the propensity score matching method. And we found BCSS and OS did not differ in the two groups (Figure [4](#F4){ref-type="fig"}, *P* = 0.812 and *P* = 0.816 for BCSS and OS, respectively).

![Kaplan-Meier plot and log-rank test compared breast cancer-specific survival (BCSS, E) and overall survival (OS, F) by histology for triple-negative breast cancer (TNBC) patients, medullary breast carcinoma (MBC) vs. invasive ductal carcinoma (IDC)](oncotarget-07-22665-g003){#F3}

![Kaplan-Meier plot and log-rank test compared breast cancer-specific survival (BCSS, G) and overall survival (OS, H) by histology for 1:1 matched triple-negative breast cancer (TNBC) patients, medullary breast carcinoma (MBC) vs. invasive ductal carcinoma (IDC)](oncotarget-07-22665-g004){#F4}

Stratification analysis with molecular subtype {#s2_5}
----------------------------------------------

In order to further investigate the effects of molecular subtype on breast cancer outcomes between MBC and IDC patients, we performed multivariate analysis, stratifying according to molecular subtype. As shown in Table [4](#T4){ref-type="table"}, when hazard ratios (HRs) of the two histological groups were conducted, no differences in BCSS and OS were observed, suggesting that molecular subtype may be a principal confounder for MBC prognosis.

###### Comparison of breast cancer-specific survival (BCSS) and overall survival (OS) between medullary breast carcinoma and invasive ductal carcinoma after subgroup analyses by multivariate Cox proportional hazard model

  Subtype                 BCSS   OS                                                           
  ----------------------- ------ ----------------------- ------- ----- ---------------------- -------
  **HR+/Her2−**                                          0.492                                0.686
  **MBC (*n* = 99)**      2      1.632 (0.404--6.595)            3     1.265 (0.406--3.945)   
  **IDC (*n* = 60267)**   282    Reference                       886   Reference              
  HR+/Her2+                                              0.997                                0.962
  **MBC (*n* = 10)**      0      --                              0     --                     
  **IDC (*n* = 9104)**    44     Reference                       142   Reference              
  **HR−/Her2+**                                          0.581                                0.971
  **MBC (*n* = 27)**      1      1.755 (0.239--12.892)           1     1.037 (0.144--7.494)   
  **IDC (*n* = 4028)**    64     Reference                       115   Reference              
  Triple negative                                        0.742                                0.535
  **MBC (*n* = 173)**     4      0.847 (0.315--2.275)            6     0.775 (0.346--1.735)   
  **IDC (*n* = 11094)**   329    Reference                       541   Reference              

Abbreviation: MBC, medullary breast carcinoma; IDC, invasive ductal carcinoma; HR, hormone receptor; Her2, human epidermal growth factor receptor 2; HRs, hazard ratios; CI, confidence interval; BCSS, breast cancer-specific survival; OS, overall survival.

*P* value was adjusted by multivariate Cox proportional hazard regression model including age, race, marital statuses, grade, tumor size, lymph node status, type of surgery, radiation and a bold type indicates significance.

DISCUSSION {#s3}
==========

In this large cohort of patients, we sought to reveal the difference in characteristics and outcomes between MBC and IDC, and summarize the prognostic factors of MBC by utilizing SEER population-based data. Our findings indicated that MBC had unique clinicalpathological characteristics and it was inclined to demonstrate more aggressive behavior over IDC. However, MBC histology presented similar prognosis in both BCSS and OS compared to IDC after adjusting and matching the confounding factors. Further stratification analysis indicated that breast cancer molecular subtype may be a principal confounder for MBC prognosis. In addition, it was exposed that married status, grade, tumor size, lymph node status, breast subtype and radiation therapy were significantly associated with BCSS and OS.

In our study, compared with the IDC group, the MBC group presented a younger age at diagnosis, higher grade, more advanced stage, larger tumor size, and higher proportion of TNBC. These observations were partially in concordance with previous studies. For example, Anderson et al. conducted an age-specific incidence rate curve and showed that MBC rates increased rapidly until age 50 and then failed to increase, while IDC rates increased rapidly until age 50 years and rose more slowly thereafter \[[@R14]\]. Park et al. demonstrated that women with MBC presented rare LN metastasis, ER and PR negativity, advanced tumor grade, and nuclear pleomorphism \[[@R12]\]. Vo et al. reported that a MBC group had larger tumors than an IDC group \[[@R10]\]. However, patients with MBC in China demonstrated less aggressive tumor features such as lower tumor stage, smaller tumor size and a lower proportion of nodal involvement than IDC \[[@R5]\].

Previous studies have revealed that MBC has a more favorable prognosis than IDC. For example, Huober et al. found that 14-year distant recurrence-free interval (DRFI), and overall survival (OS) percents for medullary tumors and invasive ductal tumors of the full cohort were 76%, 64% and 66%, 57%, respectively \[[@R15]\]. However, some interesting findings observed in our study were that compared with IDC, MBC showed nearly the same outcomes as IDC in BCSS and OS after adjusting or matching the potential confounders. Collectively, these results implied that the MBC histological type was not an independent prognostic factor. Furthermore, among TNBC patients, MBC patients presented similar survival compared with IDC patients. Therefore, we speculated that breast cancer molecular subtype may be a principal confounder for MBC prognosis and it was further verified by stratification analysis with molecular subtype. In addition, we found that worse BCSS and OS for MBC compared to IDC were seen relevance to not married status, grade III and IV, a tumor size of \> 5 cm, the increased number of lymph nodes, the subtype of TNBC and no receipt of radiation therapy.

Inevitably, our study had several limitations. In terms of follow-up data, it is the well-known fact that information regarding HER-2 expression in SEER database was not available until 2010. We were therefore compelled to focus on the short-term survival status after initial diagnosis and identify any prognostic factors and an inadequate follow-up time may give rise to the skewed results. And beyond that, differences in treatments received could influence differences in survival, but information regarding adjuvant or neoadjuvant chemotherapy is absent from the SEER database.

In conclusion, our investigations revealed that MBCs have unique clinicopathological characteristics, including a younger age at diagnosis, higher grade, more advanced stage, larger tumor size, and higher proportion of TNBC. However, MBC presented similar prognosis in both BCSS and OS compared with IDC. These results not only confer deeper insight into MBC but contribute to clinical practice that doctors ought to provide patients with MBC the same intensive treatment as those with IDC and, thereby may improve clinical management and outcomes.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We used SEER \*Stat version 8.2.1 to generate a case listing. We identified 84,764 eligible patients according to the following inclusion criteria: female, year of diagnosis from 2010 to 2012, age of diagnosis between 18 and 79 years, breast cancer as the first and only malignant cancer diagnosis, pathologically confirmed medullary breast carcinoma, not otherwise specified (MBC-NOS, ICD-O-3 8510/3) or invasive ductal carcinoma, not otherwise specified (IDC-NOS, ICD-O-3 8500/3), unilateral cancer, breast subtype, histological grades I to IV, AJCC TNM stages I-III, surgical treatment with either mastectomy or breast-conserving surgery, known ER, PR and HER2 statuses. We excluded patients who were diagnosed with breast cancer at death or by autopsy only and those with other first primary cancers, *in situ* disease, and no record of surgery type or radiation therapy. Patients diagnosed with breast cancer before 2010 were not included because the SEER database did not record data on HER2 status until 2010. Additionally, patients diagnosed with breast cancer after 2012 were not included because the database was only updated through December 31, 2012, and we wanted to ensure an adequate follow-up duration. We calculated follow-up times from January 1, 2010 to December 31, 2012.

Statistical analysis {#s4_2}
--------------------

The demographics and clinical characteristics of incorporated cases were compared between MBC and IDC groups with the Chi square test. Kaplan-Meier method was performed to generate the survival curves, and the log-rank test was performed to compare the unadjusted BCSS and OS rates of patients with different histological subtype. BCSS was measured from the date of diagnosis to the date of breast cancer death. OS was defined as the time from the date of diagnosis to the date of death due to all causes (including breast cancer) or the last follow-up. Adjusted HRs with 95% CIs were calculated using Cox proportional hazard regression models in order to estimate the prognostic factors. These above statistical analyses were performed utilizing SPSS version 20.0 software package (IBM SPSS Statistics, Chicago, IL, US). In addition, we matched each MBC patient to 1 IDC patient on the following predetermined factors: age, AJCC stage, grade, breast subtype, utilizing psmatch2 in Stata, version 12.0 (StataCorp, College Station, TX) designed for the propensity score matching methods and tested the matching quality for the balance after the match. Two-sided *P*-value \< 0.05 was considered statistically significant.
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